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ABSTRACT 
 
Purpose: To evaluate the efficacy of adjuvant subtenon carboplatin in the management 
of intraocular retinoblastoma. 
Methods: This study was conducted as a randomized, double-masked clinical trial. A 
diagnosis of intraocular retinoblastoma was made based on clinical examination, 
ultrasonography and orbital CT-scanning. The greatest basal dimension of the tumors 
was estimated in disc diameter (DD) by indirect ophthalmoscopy. Tumor thickness was 
determined by ultrasonography. Each eye was assigned to one of 10 blocks based on 
tumor stage (Reese-Ellsworth classification) and randomly received systemic 
chemotherapy alone (control group) or systemic chemotherapy plus 20mg subtenon 
carboplatin (case group). Indirect laser photocoagulation or cryotherapy was performed 
as additional treatment. 
Results: The study included 35 tumors in 17 eyes of 14 patients (19 tumors in 8 eyes in 
the control group and 16 tumors in 9 eyes in the case group). There was 57.22% and 
61.73% decrease in tumor thickness in the control and case groups, respectively. This 
difference was not statistically significant (P=0.12). The decrease in greatest basal tumor 
dimension in the control group (47.32%) was not significantly different from that in the 
case group (38.80%). One eye (12.5%) in the control group and 3 eyes (33.3%) in the case 
group were enucleated. 
Conclusion: Adjuvant   subtenon carboplatin does not seem to increase the efficacy of 
systemic chemotherapy in the treatment of intraocular retinoblastoma. 
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Introduction 
 
Retinoblastoma is the most common primary intraocular malignancy in children with an incidence 
of 1 in 15,000 live births.1 Treatment includes enucleation and external beam radiotherapy (EBRT) 
for large tumors and cryotherapy, laser therapy and plaque radiotherapy for smaller lesions.2,3 
Therapeutic modalities in retinoblastoma have changed to avoid invasive methods and reduce the 
rate of enucleation. Chemotherapy and chemoreduction are receiving increasing attention as 
effective methods for salvage of the eye.4 Chemotherapy is normally used to shrink small tumors 
which can subsequently be destroyed using adjuvant treatment such as laser therapy, cryotherapy, 
thermotherapy, chemothermotherapy, and plaque radiotherapy. The drugs most commonly used 
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for chemotherapy and chemoreduction are vincristine, etopozide, carboplatin and 
cyclophosphamide.3-6  
Considering the side effects of systemic chemotherapy, intravitreal and periocular injections of 
cytotoxic drugs have received special attention.5,6 Experimental studies in primates have shown 
tolerability to periocular carboplatin injections. Another study has reported tumor growth inhibition 
with multiple subconjuctival carboplatin injections BLHSV-40 transgenic mice.7 The short-term 
efficacy of periocular carboplatin has been reported in one case of human retinoblastoma.8 The 
purpose of the present study was to determine the effectiveness of adjuvant subtenon carboplatin in 
patients with intraocular retinoblastoma receiving systemic chemotherapy.  
 
Methods 
 
This double-masked matched randomized clinical trial was conducted on patients referred to Farabi 
Eye Hospital, Tehran, Iran from 2000 to 2002. Retinoblastoma was diagnosed by a typical tumor 
appearance on funduscopy (endophytic or exophytic) associated with signs of calcification on orbital 
CT-scan. Prior to enrollment and randomization, informed consent was obtained from patients' 
parents. 
All patients underwent examination under anesthesia. The anterior segment was examined with 
a surgical microscope, followed by tonometry using the Schiotz tonometer. Maximum basal tumor 
dimension was estimated in disc diameter by indirect ophthalmoscopy. B-scan echography was 
performed with the Nidek-US2500, and maximum tumor thickness was recorded. However, A-scan 
echography under anesthesia was not feasible. Brain and orbital CT-scan was also performed for all 
patients. Other findings such as serous retinal detachment, subretinal seeding or presence of 
subretinal fluid were also recorded. 
Patients with gross anterior segment involvement, presence of tumor cells in the anterior 
chamber, evidence of iris neovasculation, intraocular pressure over 21mmHg, hypopyon, proptosis, 
or any sign of tumor invasion and spread outside the globe on CT-scan were excluded from the 
study. The stage of the tumor was categorized using Reese-Ellsworth grouping (1a, 1b, 2a, 2b, 3a, 3b, 
4a, 4b, 5a, 5b) and then patients were randomly assigned to receive systemic chemotherapy with 
subtenon carboplatin injection or systemic chemotherapy alone. 
In the present study we administered subtenon carboplatin injection as described by Abramson 
et al. For this purpose 20mg/2ml of carboplatin (Ebewe, Austria) was injected into the subtenon 
space in the inferotemporal quadrant with a #27 needle. Topical antibiotics and steroids were 
prescribed for 1 week.  All patients were referred to a pediatric oncologist for further investigation 
and systemic chemotherapy. This assessment included clinical examination, blood biochemistry, 
urinanalysis, hepatic tests, bone marrow aspiration and CSF (cerebrospinal fluid) to determine 
possible metastasis. If metastasis was ruled out, the patient received one of two treatment protocols, 
VEC (vincristine, etoposide, carboplatin, table 1) or OPEC (oncovine, cyclophosphamide, etoposide, 
cisplatin, table 2). VEC was prescribed in patients with unilateral involvements and OPEC in 
bilateral cases. However, in some cases the oncologist changed the systemic chemotherapy program 
according to blood cell count results. 
 
Table 1. VEC therapeutic regimen 
VEC/ Day Vincristine 0.05 mg/kg 
Etoposide 
5 mg/kg 
Carboplatin 
18.6mg/kg 
0 + + + 
1 - + + 
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Table 2. OPEC therapeutic regimen 
OPEC/Day Oncovine 1.05 mg/m2 
Cyclophosphamide 
600 mg/m2 
Etoposide 
150 mg/m2 
Cisplatin 
60 mg/m2 
0 + - - + 
1 - - + - 
4 - + - - 
 
Periodic examinations under anesthesia were performed every 6-8 weeks and included B scan 
ultrasonography to record maximum tumor thickness, indirect ophthalmoscopy to document 
maximum basal dimension and thickness based on disc diameter (DD) and repeat carboplatin 
injection for the case group. The trial regimen included at least 4 carboplatin injections and 6 
sessions of VEC or 8 sessions of OPEC chemotherapy. Response to treatment was defined as 
complete, with total regression of tumor and partial when some of the active tumor mass remained.  
Recurrence was defined when active tumor mass reappeared in a tumor that had previously 
shown partial or complete response. 
In each group, possible side effects of the drug regimen were recorded. If the tumor was still 
active after injections, chemotherapy was continued. After reduction of tumor volume, laser therapy 
and cryotherapy were employed. The eye was enucleated if the tumor progressed despite treatment.  
Confluent photocoagulation was applied in 3 rows around and on the surface of the tumor as 
much as possible with chalky white intensity. Follow-up examinations were performed by a retina 
specialist unaware of the patients’ treatment protocol.  
The effect of treatment in each group was analysed using paired T-test and T-test was used to 
compare treatment effect between the two groups. Differences between frequencies of variants in 
groups were analysed using Fisher’s exact test or Mann-Whitney test. 
 
Results  
 
Overall 35 tumors in 17 eyes of 13 patients were enrolled in this study. 
A) Systemic chemotherapy 
This group included 19 tumors in 8 eyes of 8 patients 7-30 months of age (mean 15.3±8.9) 
consisting of 4 male and 4 female subjects. No positive family history was found in any case and the 
tumor was unilateral in one case and unifocal in 2 eyes. Two eyes were in stage 5b, 2 eyes were in 
stage 4 (one 4a the other 4b), 3 eyes were in stage 3 (one 3a the other two 3b) and 1 eye was in stage 
2a. Clinical characteristics are shown in table 3. 
There were 6-16 chemotherapeutic cycles (mean 8.1±2.03). VEC program was initiated in 5 
patients and after 6 sessions, one patient was shifted to OPEC. The OPEC program was initiated in 3 
patients, after 10 sessions one patient was shifted to VEC.  
Mean initial tumor thickness was 5.57±2.54 mm, which was eventually reduced to 2.36±1.20 
mm, indicating a reduction of 57.2±12.8% (p<0.001). Mean maximum basal tumor dimension at 
initiation of treatment was 8.71±6.16 disc diameter, which was reduced to 4.03±3.03 disc diameter, 
indicating a reduction of 47.3±19.6% (p=0.026).  
Mean follow-up was 12.5±2 months (range 10-15 months). During follow-up laser 
photocoagulation was performed in 3 eyes and cryotherapy in1 eye. At the end of treatment, three 
eyes (%37.5) showed complete regression, 3 eyes had partial regression, one eye (%12.5) 
demonstrated tumor recurrence and one eye (%12.5) was enucleated (table 4). No significant 
complications were observed in this group. 
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Table 3. Clinical features of eyes in the control group 
Eye Age 
(months) 
Tumor 
stage 
Growth 
pattern 
Tumor 
foci 
No of 
Tumors 
SRD SRS 
1 7 IVb E multiple 5 - + 
2 10 IIIa E multiple 2 + - 
3 7 IIa E multiple 3 - - 
4 20 IVb E multiple 3 + - 
5 7 IIIb I multiple 2 - + 
6 24 IIIb E single 1 - - 
7 18 IIIb E single 1 - - 
8 30 Vb I multiple 2 - - 
          SRD: subretinal seeding; SRS: serous retinal detachment; E: endophytic; I: infiltrative  
 
 
Table 4. Therapeutic regimen and final response in the control group. 
Eye Chemotherapy sessions Laser Cryotherapy Follow-up Response 
1 VEC (7) - - 10 complete 
2 VEC (6) OPEC (10) + - 15 recurrence 
3 OPEC(8) + - 15 partial 
4 VEC (6) OPEC (10) - + 14 complete 
5 OPEC(8) - - 10 partial 
6 VEC (6) + - 12 partial 
7 VEC (11) - - 12 complete 
8 VEC (10) - - 12 enucleated 
VEC: vincristine, etoposide, carboplatin; OPEC: oncovine, cyclophosphamide, etoposide, cisplatin  
 
B) Systemic chemotherapy plus subtenon carboplatin 
This group included 16 tumors in 9 eyes of 5 patients, consisting of 4 male and 1 female subjects 
with mean age of 19.1±17.2 months (range 7-48 months).  Family history was positive in one case.  
The tumor was unilateral in 5 eyes. Five eyes had stage 5b disease, 2 eyes were in stage 3 (one 3a 
and one 3b) and 2 eyes were in stage 2b. Clinical characteristics are shown in table 5. 
There were 6-16 chemotherapeutic cycles (mean, 9.6±4.1). In one case (No.4) after 10 OPEC 
cycles, treatment was changed to VEC. Eyes in this group received a mean of 7.6±3.1 subtenon 
carboplatin injections (range 5-15 injections). Mean follow-up was 14.5±5.05 (range 10-27) months 
(table 6). 
Mean initial tumor thickness was 9.01±3.43 mm which was reduced to 3.68±4.14 mm showing a 
61.7±29.8% reduction (p=0.004). Maximum basal tumor dimension was 9.38±2.95 disc diameter 
before treatment and was reduced to 5.36±2.99 disc diameter after treatment indicating a 38.8±28.9% 
reduction (p=0.004).  
Two eyes received laser therapy and one eye received cryotherapy. Eventually, 3 eyes (%33.3) 
were enucleated all of which were in stage 5b and one eye showed a diffuse growth pattern. Three 
eyes demonstrated complete regression and 3 eyes showed partial regression. Conjunctival 
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thickening and globe motility limitation were observed in 4 eyes which received at least 6 injections; 
one of the 4 eyes that received 7 injections, developed mild periorbital lipid atrophy. 
 
Table 5. Clinical features of eyes in the case group 
Eye Age (months) 
Tumor 
stage 
Growth 
pattern 
Tumor 
foci Tumors SRD SRS 
1 48 Vb E single 1 + - 
2 24 Vb E single 1 - - 
3 7 IIIb E single 2 + - 
4 10 Vb E multiple 3 - - 
5 12 IIb E single 1 - - 
6 48 Vb E single 3 + - 
7 7 IIIa E single 1 - - 
8 9 IIb E single 1 - - 
9 7 Vb I multiple 3 - - 
        SRD: serous retinal detachment; SRS: subretinal seeding: E: endophytic; I: infiltrative  
 
Table 6. Therapeutic regimen and final response in the case group 
Eye injections Chemotherapy sessions Laser Cryotherapy Follow-up response 
1 10 VEC (14) - - 14 enucleated 
2 15 VEC (6) + - 27 complete 
3 6 VEC (6) - - 10 complete 
4 8 OPEC(10) VEC (6) - - 15 enucleated 
5 5 VEC (6) + - 12 partial 
6 7 VEC (8) - - 14 partial 
7 6 VEC (15) - + 15 partial 
8 6 OPEC (8) - - 14 complete 
9 6 VEC (6) - - 10 enucleated 
VEC: vincristine, etoposide, carboplatin; OPEC: oncovine, cyclophosphamide, etoposide, cisplatin  
 
C) Comparison of two treatment protocols 
The study groups had comparable age and sex characteristics (P=0.10). Bilateral 
involvement was present in 7 (%87.5) and 4 (%44.4) patients in controls and cases respectively 
(p=0.131 Fisher’s exact test). Disease stage was also comparable in the two groups (p=0.1 
Mann-Whitney test). The groups were similar in terms of serous retinal detachment, subretinal 
seeding, type and number of systemic chemotherapy sessions. Follow-up duration was also 
similar (p=0.20).  
Initial tumor thickness, was significantly less in the control group (p=0.035). However 
maximum basal diameter was not significantly different in the two groups. After treatment no 
significant difference was observed in the two groups in terms of reduction in tumor thickness and 
maximal tumor basal diameter (Tables 7&8). 
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Table 7. Tumor thickness on echography before and after treatment 
 Tumor thickness    
Groups Pre-treatment Post-treatment Reduction (%) P value 
Control (n=8) 5.5±2.5 2.3±1.2 57.2±12.8 0.001 
Case (n=9) 9.0±3.4 3.6±4.1 61.7±29.8 0.004 
P Value  0.035 0.40 0.69  
 
Table 8. Basal tumor dimension on funduscopy before and after treatment 
 Basal tumor dimension (disc diameter)  
Groups Pre-treatment Post-treatment Reduction (%) P value 
Control (n=8) 8.7±6.1 4.0±3.0 47.3±19.6 0.026 
Case (n=9) 9.3±2.9 5.3±2.9 38.8±28.9 0.004 
P Value  0.77 0.37 0.49  
 
The final outcome of the treated eyes in the two groups did not show any significant difference: rate 
of complete resgression was 37.5% in the control group and 33.3% in the case group. Partial 
regression was observed in 37.5% and 33.3% of patients in the control and case groups respectively. 
Enucleation was performed in 12.5% and 33.3% of controls and cases respectively. Tumor recurrence 
occurred in 12.5% in the control group and none of the eyes in the case group (figure -1). 
 
Figure 1: Treatment response in study groups 
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Discussion 
 
Our results indicated that adjuvant subtenon carboplatin injection was not superior to systemic 
chemotherapy alone in eyes with intraocular retinoblastoma in terms of reduction in tumor size. In 
the control group 3 eyes (%37.5) had complete regression and 3 eyes had partial regression, similarly 
in the case group 3 eyes (%33.3) had complete regression and 3 eyes had partial regression. One of 8 
eyes (12.5%) in the control group and 3 of 9 eyes (%33.3) in the case group were enucleated. 
Enucleation was performed in 50% and 60% of eyes in stage 5 disease in the control and case groups 
respectively. No significant side effects or optic nerve atrophy were observed, however 4 eyes that 
received 6 or more injections had some degree of conjunctival thickness or fibrosis. 
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A previous previous animal study indicated that repeated injections of subconjuctival 
carboplatin in transgenic mouse with retinoblastoma inhibited tumor growth in 50% of the eyes. 9 
In a non-comparitive study, Abramson and colleagues, treated 13 eyes of 11 patients with 
subconjuctival carboplatin; mean number of injections for each eye was 3 times and mean injection 
interval was 21 days. However some patients had received different treatments previously, such as 
plaque radiotherapy and systemic chemotherapy. Three out of 5 eyes with vitreous involvement and 
2 of 5 eyes with retinal tumors demonstrated favorable response. One case of optic atrophy was 
observed, this patient was also receiving other focal treatment (photocoagulation and cryotherapy), 
which was considered the cause of optic nerve atrophy. One case of periorbital fat atrophy was 
reported in an eye which received seven injections.10 
In our previous study on intravitreal carboplatin injection, the globe was salvaged in 75% of 
patients receiving systemic chemotherapy alone and in 91% of patients receiving chemotherapy plus 
intravitreal carboplatin.11 However, these eyes were in lower stages of involvement than in the 
current report, and the duration of follow up was shorter. 
Shield reported 52 eyes managed with chemoreduction with 6 cycles of VEC with or without 
secondary treatment. After one year, 22% of the eyes required enucleation or EBRT but there was no 
need for enucleation in the group which received secondary treatment.12 In another study on 158 
eyes managed with 6 sessions of chemoreduction with VEC plus local treatment, Shield reported 
that 53% of eyes in stage 5 were enucleated after 28 months of follow-up13, which is comparable to 
our study.  
Gallie and colleagues reported that 88% of stage 5b cases stayed clear of recurrence within a 
short follow up period of 4 months, which shows a better response to treatment than our series.6 
However, our study had a longer duration of follow up (14 months for the treatment group and 12 
months for the control group). 
Gunduz and Shield in their study on 11 eyes in stage 5 stated that after 6 cycles of 
chemoreduction with VEC and focal treatment, 25% required EBRT or enucleation after 28 months 
of follow up.14 In a similar study Freidman reported a 23% need for EBRT or enucleation.15  
Our study was designed as a randomized matched clinical trial, which is considered one of its 
advantages. There were limitations to this study that should be considered, such as employment of 
two different systemic chemotherapy regimens, the small number of patients and lack of A-scan 
ultrasonography during examination under general anesthesia. In addition there was a chance that 
the examiner could guess the treatment group of eyes which had received multiple injections by 
their appearance.  
In conclusion although systemic chemotherapy alone was effective in reducing tumor size and 
salvage of the globe, adjuvant subtenon carboplatin injection did not increase the efficacy of such 
treatment. 
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